Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer
Open Access
- 30 September 2008
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 63 (6) , 1111-1119
Abstract
The aim of this study was to evaluate the activity and safety of oxaliplatin/5-fluorouracil-based chemo-radiotherapy in patients with not radically resectable locally advanced esophageal cancer. Fifty-nine patients with adeno or squamous-cell carcinoma received oxaliplatin (60 mg/m2), and leucovorin (20 mg/m2 on days 1,8,15,29,36,43,50,57) followed by continuous infusion fluorouracil (200 mg/m2 per day on days 1–22 and 29–64) with radiotherapy (1.8 Gy daily fractions to a total dose of 45 Gy, from days 29 to 64). When feasible, surgery was scheduled 6–8 weeks after chemo-radiotherapy completion. The primary endpoint was 1-year progression-free survival. Forty (68%) patients completed treatment without modifications. An objective clinical response was seen in 35 patients (59%). Esophagectomy was possible in 33 patients and a complete resection (R0) was achieved in 26 (79%) with 6 pathologic complete responses (pCR) and 3 near pCR. At a median follow-up of 39.7 months for the surviving patients, the median progression-free and overall survivals were 11 months (95% CI 6.5–14) and 18.5 months (95% CI 13–29). The 1-year progression-free and overall survivals were 47.5% (95% CI 34–59.5%) and 63% (95% CI 49–74%). Major toxicities were esophagitis (20% G3 and 5% G4) and diarrhea (8.5% G3 and 8.5% G4). Hematological toxicity (7% G3 and 3% G4) was less common; severe neurotoxicity (3% G3) was infrequent. Concurrent oxaliplatin, leucovorin, fluorouracil and radiotherapy followed or not by esophagectomy has a tolerable toxicity and promising activity in locally advanced esophageal cancer.Keywords
This publication has 41 references indexed in Scilit:
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische OnkologieJournal of Clinical Oncology, 2008
- Chemoradiation Followed by Surgery Compared With Chemoradiation Alone in Squamous Cancer of the Esophagus: FFCD 9102Journal of Clinical Oncology, 2007
- Phase II trial of docetaxel, cisplatin and fluorouracil followed by carboplatin and radiotherapy in locally advanced oesophageal cancerBritish Journal of Cancer, 2007
- A phase I–II study of weekly oxaliplatin, 5-fluorouracil continuous infusion and preoperative radiotherapy in locally advanced rectal cancerAnnals of Oncology, 2005
- Dose–response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Radiochemotherapy with short daily infusion of low-dose oxaliplatin, leucovorin, and 5-FU in T3–T4 unresectable rectal cancer: a phase II IATTGI studyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinomaCancer, 2001
- Chemoradiotherapy of Locally Advanced Esophageal CancerJAMA, 1999
- 202 Oxaliplatin: In vitro evidence of its radiation sensitizing activity — preclinical observations relevant to clinical trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Combined Chemotherapy and Radiotherapy Compared with Radiotherapy Alone in Patients with Cancer of the EsophagusNew England Journal of Medicine, 1992